<DOC>
	<DOCNO>NCT00358826</DOCNO>
	<brief_summary>This dose range study compare effect VIA-2291 v . Placebo various inflammatory biomarkers patient recent acute coronary event</brief_summary>
	<brief_title>Study Effect VIA-2291 Vascular Inflammation</brief_title>
	<detailed_description>This Phase II , randomize , double-blind , placebo-controlled study effect VIA-2291 atherosclerotic vascular inflammation</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atreleuton</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>Female patient nonchildbearing potential Patient suffer ST elevation myocardial infarction ( MI ) , nonST elevation MI , unstable angina 21 day ( Â±3 day ) prior study randomization Patient document coronary artery disease Renal insufficiency define creatinine &gt; 1.5 x upper limit normal ( ULN ) Cirrhosis , recent hepatitis , ALT &gt; 1.5 x ULN ALT &gt; 1 x ULN least one liver function test Uncontrolled diabetes mellitus within 1 month prior study screen Congestive heart failure ( CHF ) define New York Heart Association functional Class III IV Previous coronary artery bypass graft ( CABG ) surgery Planned additional cardiac intervention Recurrence ST elevation MI , nonST elevation MI , unstable angina le 18 day prior randomization Current atrial fibrillation , atrial flutter , frequent premature ventricular contraction Acetaminophen use form 7 day enrollment</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>